Omega-3 index and cardiovascular health

Nutrients

Volumn 6, Issue 2, 2014, Pages 799-814

  von Schacky, Clemens ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Omegametrix GmbH   (Germany)

Author keywords

Cardiovascular disease; Cardiovascular prevention; Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3 index

Indexed keywords

DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; FOOD FREQUENCY QUESTIONNAIRE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; REVIEW; SUDDEN CARDIAC DEATH;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84895195020     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6020799     Document Type: Review

References (101)

1. Burr, M.L.; Fehily, A.M.; Gilbert, J.F.; Rogers, S.; Holliday, R.M.; Sweetnam, P.M.; Elwood, P.C.; Deadman, N.M. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: Diet and reinfarction trial (DART). Lancet 1989, 2, 757-761.
2. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354, 447-455.
3. Marchioli, R.; Barzi, F.; Bomba. E.; Chieffo, C.; di Gregorio, D.D.M.R.; Franzosi, M.G.; Geraci, E.; Levatesi, G.; Maggioni, A.P.; Mantini, L.; et al Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardio (GISSI)-Prevenzione. Circulation 2002, 105, 1897-1903.
4. Svensson, M.; Schmidt, E.B.; Jørgensen, K.A.; Christensen, J.H.; OPACH Study Group. n-3 Fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: A randomized, placebo-controlled intervention trial. Clin J Am Soc. Nephrol 2006, 1, 780-786.
5. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090-1098.
6. Gissi-HF Investigators; Tavazzi, L.; Maggioni, A.P.; Marchioli, R.; Barlera, S.; Franzosi, M.G.; Latini, R.; Lucci, D.; Nicolosi, G.L.; Porcu, M.; et al Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1223-1230.
7. Galan, P.; Kesse-Guyot, E.; Czernichow, S.; Briancon, S.; Blacher, J.; Hercberg, S.; SU. FOL. OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. Br Med J 2010, 341, c6273.
8. Rauch, B.; Schiele, R.; Schneider, S.; Diller, F.; Victor, N.; Gohlke, H.; Gottwik, M.; Steinbeck, G.; del Castillo, U.; Sack, R.; et al OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122, 2152-2159.
9. Einvik, G.; Klemsdal, T.O.; Sandvik, L.; Hjerkinn, E.M. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2010, 17, 588-592.
10. Kromhout, D.; Giltay, E.J.; Geleijnse, J.M.; Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363, 2015-2026.
11. ORIGIN Trial Investigators; Bosch, J.; Gerstein, H.C.; Dagenais, G.R.; Díaz, R.; Dyal, L.; Jung, H.; Maggiono, A.P.; Probstfield, J.; Ramachandran, A.; et al n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2011, 367, 319-328.
12. Risk and Prevention Study Collaborative Group; Roncaglioni, M.C.; Tombesi, M.; Avanzini, F.; Barlera, S.; Caimi, V.; Longoni, P.; Marzona, I.; Milani, V.; Silletta, M.G.; et al n-3 Fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013, 368, 1800-1808.
13. Chowdhury, R.; Stevens, S.; Gorman, D.; Pan, A.; Warnakula, S.; Chowdhury, S.; Ward, H.; Johnson. L.; Crowe, F.; Hu, F.B.; et al Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: Systematic review and meta-analysis. Br Med J 2012, 345, e6698.
14. Kotwal, S.; Jun, M.; Sullivan, D.; Perkovic, V.; Neal, B. Omega 3 fatty acids and cardiovascular outcomes: Systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2012, 5, 808-818.
15. Rizos, E.C.; Ntzani, E.E.; Bika, E.; Kostapanos, M.S.; Elisaf, M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. J Am Med Assoc 2012, 308, 1024-1033.
16. Kwak, S.M.; Myung, S.K.; Lee, Y.J.; Seo, H.G.; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern. Med 2012, 172, 686-694.
17. Delgado-Lista, J.; Perez-Martinez, P.; Lopez-Miranda, J.; Perez-Jimenez, F. Long chain omega-3 fatty acids and cardiovascular disease: A systematic review. Br J Nutr 2012, 107, S201-S213.
18. Mozaffarian, D.; Rimm, E.B. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. J Am Med Assoc 2006, 296, 1885-1899.
19. Hu, F.B.; Bronner, L.; Willett, W.C.; Stampfer, M.J.; Rexrode, K.M.; Albert, C.M.; Hunter, D.; Manson, J.E. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. J Am Med Assoc 2002, 287, 1815-1821.
20. Siscovick, D.S.; Raghunathan, T.E.; King, I.; Weinmann, S.; Wicklund, K.G.; Albright, J.; Bovbjerg, V.; Arbogast, P.; Smith, H.; Kushi, L.H. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J Am. Med Assoc 1995, 275, 836-837.
21. Albert, C.M.; Campos, H.; Stampfer, M.J.; Ridker, P.M.; Manson, J.E.; Willett, W.C.; Ma, J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346, 1113-1118.
22. Smith, S.C., Jr.; Benjamin, E.J.; Bonow, R.O.; Braun, L.T.; Creager, M.A.; Franklin, B.A.; Gibbons, R.J.; Grundy, S.M.; Hiratzka, L.F.; Jones, D.W.; et al AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: A guideline from the american heart association and american college of cardiology foundation. Circulation 2011, 124, 2458-2473.
23. Perk, J.; de Backer, G.; Gohlke, H.; Graham, I.; Reiner, Z.; Verschuren, M.; Albus, C.; Benlian, P.; Boysen, G.; Cifkova, R.; et al European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33, 1635-1701.
24. Fihn, S.D.; Gardin, J.M.; Abrams, J.; Berra, K.; Blankenship, J.C.; Dallas, A.P.; Douglas, P.S.; Foody, J.M.; Gerber, T.C.; Hinderliter, A.L.; et al 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American college of cardiology foundation/american heart association task force on practice guidelines, and the american college of physicians, american association for thoracic surgery, preventive cardiovascular nurses association, of thoracic surgeons. Circulation 2012, 126, e354-e471.
25. Steg, P.G.; James, S.K.; Atar, D.; Badano, L.P.; Blömstrom-Lundqvist, C.; Borger, M.A.; di Mario, C.; Dickstein, K.; Ducrocq, G.; et al ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33, 2569-2619.
26. Mozaffarian, D.; Psaty, B.M.; Rimm, E.B.; Lemaitre, R.N.; Burke, G.L.; Lyles, M.F.; Lefkowitz, D.; Siscovick, D.S. Fish intake and risk of incident atrial fibrillation. Circulation 2004, 110, 368-373.
27. Wu, J.H.; Lemaitre, R.N.; King, I.B.; Song, X.; Sacks, F.M.; Rimm, E.B.; Heckbert, S.R.; Siscovick, D.S.; Mozaffarian, D. Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: The cardiovascular health study. Circulation 2012, 125, 1084-1093.
28. Mozaffarian, D.; Wu, J.H.; de Oliveira Otto, M.C.; Sandesara, C.M.; Metcalf, R.G.; Latini, R.; Libby, P.; Lombardi, F.; O'Gara, P.T.; Page, R.L.; et al Fish oil and post-operative atrial fibrillation: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2013, 61, 2194-2196.
29. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; can Gelder, I.C.; Al-Attar, N.; et al Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur Heart J 2010, 31, 2369-2429.
30. Brouwer, I.A.; Raitt, M.H.; Dullemeijer, C.; Kraemer, D.F.; Zock, P.L.; Morris, C.; Katan, M.B.; Connor, W.E.; Camm, J.A.; Schouten, E.G.; et al Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009, 30, 820-826.
31. Zipes, D.P.; Camm, A.J.; Borggrefe, M.; Buxton, A.E.; Chaitman, B.; Fromer, M.; Gregoratos, G.; Klein, G.; Moss, A.J.; Myerburg, R.J.; et al ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-Executive summary: A report of the American college of cardiology/American heart association task force and the european society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European heart rhythm association and the heart rhythm society. Eur Heart J 2006, 27, 2099-2140.
32. Archer, E.; Hand, G.A.; Blair, S.N. Validity of U.S. nutritional surveillance: National Health and Nutrition Examination Survey caloric energy intake data, 1971-2010. PLoS One 2013, 8, e76632.
33. De Oliveira Otto, M.C.; Wu, J.H.; Baylin, A.; Vaidya, D.; Rich, S.S.; Tsai, M.Y.; Jacobs, D.R.; Mozaffarian, D. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013, 2, e000506.
34. Harris, W.S.; von Schacky, C.; Park, Y. Standardizing Methods for Assessing Omega-3 Biostatus. In The Omega-3 Deficiency Syndrome; McNamara, R.K., Ed.; Nova Publishers: Hauppauge, NY, USA, 2013; pp. 385-398.
35. Von Schacky, C.; Fischer, S.; Weber, P.C. Long term effects of dietary marine omega-3 fatty acids upon plasma-and cellular lipids, platelet function and eicosanoid formation in humans. J Clin Investig. 1985, 76, 1626-1631.
36. Harris, W.S.; Sands, S.A.; Windsor, S.L.; Ali, H.A.; Stevens, T.L.; Magalski, A.; Porter, C.B.; Borkon, A.M. Omega-3 fatty acid levels in transplanted human hearts: Effect of supplementation and comparison with erythrocytes. Circulation 2004, 110, 1645-1649.
37. Arnold, C.; Markovic, M.; Blossey, K.; Wallukat, G.; Fischer, R.; Dechend, R.; Konkel, A.; von Schacky, C.; Luft, F.C.; Muller, D.N.; et al Arachidonic acid-metabolizing cytochrome P-450 enzymes are targets of omega-3 fatty acids. J Biol Chem 2010, 285, 32720-32733.
38. Harris, W.S.; Thomas, R.M. Biological variability of blood omega-3 biomarkers. Clin Biochem. 2010, 43, 338-340.
39. Harris, W.S.; von Schacky, C. The omega-3 index: A new risk factor for death from CHD? Prev Med 2004, 39, 212-220.
40. Hlatky, M.A.; Greenland, P.; Arnett, D.K.; Ballantyne, C.M.; Criqui, M.H.; Elkind, M.S.; Go, A.S.; Harrell, F.E., Jr.; Hong, Y.; Howard, B.V.; et al American heart association expert panel on subclinical atherosclerotic diseases and emerging risk factors and the stroke council. Circulation 2009, 119, 2408-2416.
41. Helfand, M.; Buckley, D.I.; Freeman, M.; Fu, R.; Rogers, K.; Fleming, C.; Humphrey, L.L. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. preventive services task force. Ann Intern Med 2009, 151, 496-507.
42. Köhler, A.; Bittner, D.; Löw, A.; von Schacky, C. Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br J Nutr 2010, 104, 729-736.
43. Neubronner, J.; Schuchardt, J.P.; Kressel, G.; Merkel, M.; von Schacky, C.; Hahn, A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides vs ethyl esters. Eur J Clin Nutr 2011, 65, 247-254.
44. Baghai, T.C.; Varallo-Bedarida, G.; Born, C.; Häfner, S.; Schüle, C.; Eser, D.; Rupprecht, R.; Bondy, B.; von Schacky, C. Major depression is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiatry 2011, 72, 1242-1247.
45. Sala-Vila, A.; Harris, W.S.; Cofán, M.; Pérez-Heras, A.M.; Pintó, X.; Lamuela-Raventós, R.M.; Covas, M.I.; Estruch, R.; Ros, E. Determinants of the omega-3 index in a Mediterranean population at increased risk for CHD. Br J Nutr 2011, 106, 425-431.
46. Aarsetoey, H.; Pönitz, V.; Nilsen, O.B.; Grundt, H.; Harris, W.S.; Nilsen, D.W. Low levels of cellular omega-3 increases the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008, 78, 258-264.
47. Sands, S.A.; Reid, K.J.; Windsor, S.L.; Harris, W.S. The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 2005, 40, 343-347.
48. Harris, W.S.; Pottala, J.V.; Vasan, R.S.; Larson, M.G.; Robins, S.J. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans. J Nutr 2012, 142, 1297-1303.
49. Pottala, J.V.; Garg, S.; Cohen, B.E.; Whooley, M.A.; Harris, W.S. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: The heart and soul study. Circ Cardiovasc Qual Outcomes 2010, 3, 406-412.
50. Amin, A.A.; Menon, R.A.; Reid, K.J.; Harris, W.S.; Spertus, J.A. Acute coronary syndrome patients with depression have low blood cell membrane omega-3 fatty acid levels. Psychosom Med 2008, 70, 856-862.
51. Pottala, J.V.; Churchill, S.W.; Talley, J.A.; Lynch, D.A.; von Schacky, C.; Harris, W.S. Red blood cell fatty acids are associated with depression in a case-control study of adolescents. Prostaglandins Leukot Essent Fatty Acids 2012, 86, 161-165.
52. Ladesich, J.B.; Pottala, J.V.; Romaker, A.; Harris, W.S.; Membrane levels of omega-3 docosahexaenoic acid is associated with obstructive sleep apnea. J Clin Sleep Med 2011, 7, 391-396.
53. Park, Y.; Lim, J.; Lee, J.; Kim, S.G. Erythrocyte fatty acid profiles can predict acute non-fatal myocardial infarction. Br J Nutr 2009, 102, 1355-1356.
54. Park, Y.; Park, S.; Yi, H.; Kim, H.Y.; Kang, S.J.; Kim, J.; Ahn, H. Low level of n-3 polyunsaturated fatty acids in erythrocytes is a risk factor for both acute ischemic and hemorrhagic stroke in Koreans. Nutr Res 2009, 29, 825-830.
55. Son, Y.K.; Lee, S.M.; Kim, S.E.; Kim, K.H.; Lee, S.Y.; Bae, H.R.; Han, J.Y.; Park, Y.; An, W.S. Association between vascular calcification scores on plain radiographs and fatty acid contents of erythrocyte membrane in hemodialysis patients. J Ren Nutr 2012, 22, 58-66.
56. An, W.S.; Kim, S.E.; Kim, K.H.; Lee, S.; Park, Y.; Kim, H.J.; Vaziri, N.D. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009, 19, 267-274.
57. Oh, J.S.; Kim, S.M.; Sin, Y.H.; Kim, J.K.; Park, Y.; Bae, H.R.; Son, Y.K.; Nam, H.K.; Kang, H.J.; An, W.S. Comparison of erythrocyte membrane fatty acid contents in renal transplant recipients and dialysis patients. Transplant Proc 2012, 44, 2932-2935.
58. Harris, W.S.; Varvel, S.A.; Pottala, J.V.; Warnick, G.R.; McConnell, J.P. The comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility. J Clin Lipidol 2013, 7, 433-440.
59. Shearer, G.C.; Chen, J.; Chen, Y.; Harris, W.S. Myocardial infarction does not affect fatty acid profiles in rats. Prostaglandins Leukot Essent Fatty Acids 2009, 81, 411-416.
60. Aarsetøy, H.; Aarsetøy, R.; Lindner, T.; Staines, H.; Harris, W.S.; Nilsen, D.W.T. Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids 2011, 46, 151-161.
61. Flock, M.R.; Skulas-Ray, A.C.; Harris, W.S.; Etherton, T.D.; Fleming, J.A.; Kris-Etherton, P.M. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: A dose-response randomized controlled trial. J Am Heart Assoc 2013, 2, e000513.
62. Ebbesson, S.O.; Devereux, R.B.; Cole, S.; Ebbesson, L.O.; Fabsitz, R.R.; Haack, K.; Harris, W.S.; Howard, W.J.; Laston, S.; Lopez-Alvarenga, J.C.; et al Heart rate is associated with red blood cell fatty acid concentration: The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study. Am Heart J 2010, 159, 1020-1025.
63. Harris, W.S.; Pottala, J.V.; Lacey, S.M.; Vasan, R.S.; Larson, M.G.; Robins, S.J. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis 2012, 225, 425-431.
64. Cohen, B.E.; Garg, S.K.; Ali, S.; Harris, W.S.; Whooley, M.A. Red blood cell EPA and DHA concentrations are positively associated with socioeconomic status in patients with established coronary artery disease: Data from the Heart and Soul Study. J Nutr 2008, 138, 1135-1140.
65. Block, R.C.; Harris, W.S.; Pottala, J.V. Determinants of blood cell omega-3 fatty acid content. Open Biomark J 2008, 1, 1-6.
66. Farzaneh-Far, R.; Harris, W.S.; Garg, S.; Na, B.; Whooley, M.A. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 2009, 205, 538-543.
67. An, W.S.; Son, Y.K.; Kim, S.E.; Kim, K.H.; Bae, H.R.; Lee, S.; Park, Y.; Kim, H.J.; Vaziri, N.D. Association of adiponectin and leptin with serum lipids and erythrocyte omega-3 and omega-6 fatty acids in dialysis patients. Clin Nephrol 2011, 75, 195-203.
68. Salisbury, A.C.; Amin, A.P.; Harris, W.S.; Chan, P.S.; Gosch, K.L.; Rich, M.W.; O'Keefe, J.H., Jr.; Spertus, J.A. Predictors of omega-3 index in patients with acute myocardial infarction. Mayo Clin Proc 2011, 86, 626-632.
69. Jo, S.; An, W.S.; Park Y. Erythrocyte n-3 polyunsaturated fatty acids and the risk of type 2 diabetes in Koreans: A case-control study. Ann. Nutr. Metab. 2013, 63, 283-290.
70. Park, Y.; Kim, M. Serum 25-hydroxyvitamin D concentrations are associated with erythrocyte levels of n-3 PUFA but not risk of CVD. Br J Nutr 2011, 106, 1529-1534.
71. Grenon, S.M.; Conte, M.S.; Nosova, E.; Alley, H.; Chong, K.; Harris, W.S.; Vittinghoff, E.; Owens, C.D. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg 2013, 58, 1283-1290.
72. Harris, W.S.; Poston, W.C.; Haddock, C.K. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007, 193, 1-10.
73. Superko, H.R.; Superko, S.M.; Nasir, K.; Agatston, A.; Garrett, B.C. Omega-3 fatty acid blood levels: Clinical significance and controversy. Circulation 2013, 128, 2154-2161.
74. Harris, W.S.; Kennedy, K.F.; O'Keefe, J.H., Jr.; Spertus, J.A. Red blood cell fatty acid levels improve GRACE score prediction of 2-year mortality in patients with myocardial infarction. Int J. Cardiol 2013, 168, 53-59.
75. Shearer, G.C.; Pottala, J.V.; Spertus, J.A.; Harris, W.S. Red blood cell fatty acid patterns and acute coronary syndrome. PLoS One 2009, 4, e5444.
76. Abuannadi, M.; O'Keefe, J.H.; Spertus, J.A.; Kennedy, K.F.; Harris, W.S. Omega-3 Index: An Independent Predictor of 1 Year All Cause Mortality in Myocardial Infarction (MI) Patients. Poster 174, AHA QCOR Meeting, 19-21 May 2010. Available online: http://my.americanheart.org/ idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_319392.pdf (accessed on 15 January 2014).
77. Aarsetoey, H.; Pönitz, V.; Grundt, H.; Staines, H.; Harris, W.S.; Nilsen, D.W. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J Nutr 2009, 139, 507-513.
78. Harris, W.S.; Reid, K.J.; Sands, S.A.; Spertus, J.A. Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am J Cardiol 2007, 99, 154-158.
79. Block, R.C.; Harris, W.S.; Reid, K.J.; Sands, S.A.; Spertus, J.A. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2008, 197, 821-828.
80. Kim, Y.J.; Jeong, D.W.; Lee, J.G.; Lee, H.C.; Lee, S.Y.; Kim, Y.J.; Yi, Y.H.; Park, Y.S.; Cho, Y.H.; Bae, M.J.; et al Omega-3 index and smoking in patients with acute ST-elevation myocardial infarction taking statins: A case-control study in Korea. Lipids Health Dis. 2012, 11, 43.
81. Harris, W.S.; Gonzales, M.; Laney, N.; Sastre, A.; Borkon, A.M. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. Am J Cardiol 2006, 98, 1393-1395.
82. Harris, W.S.; Pottala, J.V.; Sands, S.A.; Jones, P.G. Comparison of the effects of fish and fish oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 2007, 86, 1621-1625.
83. Larson, M.K.; Ashmore, J.H.; Harris, K.A.; Vogelaar, J.L.; Pottala, J.V.; Sprehe, M.; Harris, W.S. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008, 100, 634-641.
84. Carney, R.M.; Freedland, K.E.; Stein, P.K.; Steinmeyer, B.C.; Harris, W.S.; Rubin, E.H.; Krone, R.J.; Rich, M.W. Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosom Med 2010, 72, 748-754.
85. Skulas-Ray, A.C.; Kris-Etherton, P.M.; Harris, W.S.; Vanden Heuvel, J.P.; Wagner, P.R.; West, S.G. Dose response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy people with moderate hypertriglyceridemia. Am J Clin Nutr. 2011, 93, 243-252.
86. Schuchardt, J.P.; Neubronner, J.; Kressel, G.; Merkel, A.; von Schacky, C.; Hahn, A. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids 2011, 85, 381-386.
87. Dewell, A.; Marvasti, F.F.; Harris, W.S.; Tsao, P.; Gardner, C.D. Dose-dependent effects of plant and marine omega-3 fatty acids on inflammatory markers in insulin resistant adults. A randomized controlled trial. J Nutr 2011, 141, 2166-2171.
88. Maki, K.C.; Bays, H.E.; Dicklin, M.R.; Johnson, S.L.; Shabbout, M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011, 5, 483-492.
89. Krul, E.S.; Lemke, S.L.; Mukherjea, R.; Taylor, M.L.; Goldstein, D.A.; Su, H.; Liu, P.; Lawless, A.; Harris, W.S.; Maki, K.C. Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content. Prostaglandins Leukot Essent. Fatty Acids 2012, 86, 51-59.
90. An, W.S.; Lee, S.M.; Son, Y.K.; Kim, S.E.; Kim, K.H.; Han, J.Y.; Bae, H.R.; Park, Y. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent, Fatty Acids 2012, 86, 29-34.
91. Shearer, G.C.; Pottala, J.V.; Hansen, S.N.; Brandenburg, V.; Harris, W.S. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: A randomized controlled trial. J Lipid Res 2012, 53, 2429-2435.
92. Skulas-Ray, A.C.; Kris-Etherton, P.M.; Harris, W.S.; West, S.G. Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: A dose-response study. Ann Behav Med 2012, 44, 301-308.
93. Keenan, A.H.; Pedersen, T.L.; Fillaus, K.; Larson, M.K.; Shearer, G.C.; Newman, J.W. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n-3-HUFA in healthy volunteers. J Lipid Res 2012, 53, 1662-1669.
94. Block, R.C.; Dier, U.; Calderonartero, P.; Shearer, G.C.; Kakinami, L.; Larson, M.K.; Harris, W.S.; Georas, S.; Mousa, S.A. The effects of EPA + DHA and aspirin on inflammatory cytokines and angiogenesis factors. World J Cardiovasc Dis 2012, 2, 14-19.
95. Von Schacky, C.; Angerer, P.; Kothny, W.; Theisen, K.; Mudra, H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind placebo-controlled trial. Ann Int Med 1999, 130, 554-562.
96. Schuchardt, J.P.; Hahn, A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2013, 89, 1-8.
97. Dyerberg, J.; Madsen, P.; Møller, J.M.; Aardestrup, I.; Schmidt, E.B. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids 2010, 83, 137-41.
98. Davidson, M.H.; Johnson, J.; Rooney, M.W.; Kyle, M.L.; Kling, D.F. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol 2012, 6, 573-584.
99. Hussey, E.K.; Portelli, S.; Fossler, M.J.; Gao, F.; Harris, W.S.; Blum, R.A.; Lates, C.D.; Gould, E.; Abu-Baker, O.; Johnson, S.; et al Relative bioavailability of an emulsion formulation for omega-3-acid ethyl esters compared to the commercially available formulation: A randomized, parallel-group, single-dose study followed by repeat dosing in healthy volunteers. Clin Pharm Drug Dev 2012, 1, 14-23.
100. Makrides, M.; Gibson, R.A.; McPhee, A.J.; Yelland, L.; Quinlivan, J.; Ryan, P. DOMInO Investigative Team. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: A randomized controlled trial. J Am Med Assoc 2010, 304, 1675-1683.
101. Montgomery, P.; Burton, J.R.; Sewell, R.P.; Spreckelsen, T.F.; Richardson, A.J. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: A cross-sectional analysis from the DOLAB study. PLoS One 2013, 8, e66697.